These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 37287599)

  • 1. A claims-based, machine-learning algorithm to identify patients with pulmonary arterial hypertension.
    Hyde B; Paoli CJ; Panjabi S; Bettencourt KC; Bell Lynum KS; Selej M
    Pulm Circ; 2023 Apr; 13(2):e12237. PubMed ID: 37287599
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and evaluation of a predictive algorithm for unsatisfactory response among patients with pulmonary arterial hypertension using health insurance claims data.
    Gauthier-Loiselle M; Tsang Y; Lefebvre P; Agron P; Royer J; Bell Lynum KS; Bennett L; Panjabi S
    Curr Med Res Opin; 2022 Jun; 38(6):1019-1030. PubMed ID: 35243952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic Burden of Delayed Diagnosis in Patients with Pulmonary Arterial Hypertension (PAH).
    DuBrock HM; Germack HD; Gauthier-Loiselle M; Linder J; Satija A; Manceur AM; Cloutier M; Lefebvre P; Panjabi S; Frantz RP
    Pharmacoecon Open; 2024 Jan; 8(1):133-146. PubMed ID: 37980316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Time to diagnosis of pulmonary hypertension and diagnostic burden: A retrospective analysis of nationwide US healthcare data.
    Didden EM; Lee E; Wyckmans J; Quinn D; Perchenet L
    Pulm Circ; 2023 Jan; 13(1):e12188. PubMed ID: 36694845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Excess healthcare resource utilization and costs for commercially insured patients with pulmonary arterial hypertension: A real-world data analysis.
    Weiss T; Ramey DR; Pham N; Shaikh NF; Tian D; Zhao X; Near AM; Lautsch D; Nathan SD
    Pulm Circ; 2024 Apr; 14(2):e12390. PubMed ID: 38903484
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-World Treatment Patterns Among Patients with Connective Tissue Disorder-Related Pulmonary Arterial Hypertension in the United States: A Retrospective Claims-Based Analysis.
    Sargent T; Tsang Y; Panjabi S; Funtanilla V; Germack HD; Gauthier-Loiselle M; Manceur AM; Cloutier M; Lefebvre P
    Adv Ther; 2023 Nov; 40(11):5037-5054. PubMed ID: 37728697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hospitalization Among Pulmonary Arterial Hypertension Patients With and Without Connective Tissue Disease Comorbidities Prescribed Oral Selexipag.
    Tsang Y; Singh R; Verma S; Panjabi S
    Rheumatol Ther; 2023 Jun; 10(3):741-756. PubMed ID: 36959524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hospitalization-related costs associated with oral agents targeting the prostacyclin pathway for pulmonary arterial hypertension.
    McConnell J; Bilir SP; Xu Y; Tsang Y; Panjabi S
    J Med Econ; 2023; 26(1):1349-1355. PubMed ID: 37800591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of selexipag use within 12 months of pulmonary arterial hypertension diagnosis on hospitalizations and medical costs: A retrospective cohort study.
    Tsang Y; Stokes M; Kim YJ; Tilney R; Panjabi S
    Clin Respir J; 2023 Dec; 17(12):1209-1222. PubMed ID: 37804160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economic burden of illness among patients with pulmonary arterial hypertension (PAH) associated with connective tissue disorders (CTD).
    Tsang Y; Panjabi S; Funtanilla V; Germack HD; Gauthier-Loiselle M; Manceur AM; Liu S; Cloutier M; Lefebvre P
    Pulm Circ; 2023 Apr; 13(2):e12218. PubMed ID: 37051491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterizing pulmonary hypertension-related hospitalization costs among Medicare Advantage or commercially insured patients with pulmonary arterial hypertension: a retrospective database study.
    Burke JP; Hunsche E; Régulier E; Nagao M; Buzinec P; Drake Iii W
    Am J Manag Care; 2015 Jan; 21(3 Suppl):s47-58. PubMed ID: 25734573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of Healthcare Encounters and Drug Persistence in Patients With Pulmonary Arterial Hypertension Receiving Oral Selexipag, Inhaled Iloprost, or Parenteral Treprostinil: A Retrospective Database Analysis.
    Song C; Kunovszki P; Beaudet A
    J Health Econ Outcomes Res; 2022; 9(1):151-160. PubMed ID: 35800882
    [No Abstract]   [Full Text] [Related]  

  • 13. Machine Learning Algorithm Helps Identify Non-Diagnosed Prodromal Alzheimer's Disease Patients in the General Population.
    Uspenskaya-Cadoz O; Alamuri C; Wang L; Yang M; Khinda S; Nigmatullina Y; Cao T; Kayal N; O'Keefe M; Rubel C
    J Prev Alzheimers Dis; 2019; 6(3):185-191. PubMed ID: 31062833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Healthcare resource utilization and costs for patients with pulmonary arterial hypertension: real-world documentation of functional class.
    Dufour R; Pruett J; Hu N; Lickert C; Stemkowski S; Tsang Y; Lane D; Drake W
    J Med Econ; 2017 Nov; 20(11):1178-1186. PubMed ID: 28762848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A machine learning cardiac magnetic resonance approach to extract disease features and automate pulmonary arterial hypertension diagnosis.
    Swift AJ; Lu H; Uthoff J; Garg P; Cogliano M; Taylor J; Metherall P; Zhou S; Johns CS; Alabed S; Condliffe RA; Lawrie A; Wild JM; Kiely DG
    Eur Heart J Cardiovasc Imaging; 2021 Jan; 22(2):236-245. PubMed ID: 31998956
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medication use by US patients with pulmonary hypertension associated with chronic obstructive pulmonary disease: a retrospective study of administrative data.
    Weiss TJ; Rosen Ramey D; Yang L; Liu X; Patel MJ; Rajpathak S; Bajwa EK; Lautsch D
    BMC Pulm Med; 2022 Oct; 22(1):383. PubMed ID: 36258171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Claims-Based Algorithms for Identifying Patients With Pulmonary Hypertension: A Comparison of Decision Rules and Machine-Learning Approaches.
    Ong MS; Klann JG; Lin KJ; Maron BA; Murphy SN; Natter MD; Mandl KD
    J Am Heart Assoc; 2020 Oct; 9(19):e016648. PubMed ID: 32990147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Excess costs associated with patients with pulmonary arterial hypertension in a US privately insured population.
    Kirson NY; Birnbaum HG; Ivanova JI; Waldman T; Joish V; Williamson T
    Appl Health Econ Health Policy; 2011 Sep; 9(5):293-303. PubMed ID: 21875160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative evaluation of costs and healthcare resource utilization of oral selexipag versus inhaled treprostinil or oral treprostinil in patients with pulmonary arterial hypertension.
    Papademetriou E; Liu X; Beaudet A; Tsang Y; Potluri R; Panjabi S
    J Med Econ; 2023; 26(1):644-655. PubMed ID: 37086091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A machine learning approach to identifying patients with pulmonary hypertension using real-world electronic health records.
    Kogan E; Didden EM; Lee E; Nnewihe A; Stamatiadis D; Mataraso S; Quinn D; Rosenberg D; Chehoud C; Bridges C
    Int J Cardiol; 2023 Mar; 374():95-99. PubMed ID: 36528138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.